Almirall Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Almirall è una società che paga dividendi con un rendimento attuale di 2.16%.

Informazioni chiave

2.2%

Rendimento del dividendo

-0.007%

Rendimento del riacquisto

Rendimento totale per gli azionisti	2.2%
Rendimento futuro dei dividendi	2.2%
Crescita dei dividendi	15.2%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	€0.184
Rapporto di remunerazione	-107%

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 14

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Nov 06

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Sep 07

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Jul 12

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Sebbene i pagamenti dei dividendi siano rimasti stabili, ALM paga dividendi da meno di 10 anni.

Dividendo in crescita: ALM paga dividendi solo da 9 anni e da allora i pagamenti sono diminuiti.

Rendimento dei dividendi rispetto al mercato

Almirall Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di ALM rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (ALM)	2.2%
Fondo del 25% del mercato (ES)	2.4%
Top 25% del mercato (ES)	5.5%
Media del settore (Pharmaceuticals)	2.5%
Analista previsionale (ALM) (fino a 3 anni)	2.2%

Dividendo notevole: Il dividendo di ALM ( 2.16% ) non è degno di nota rispetto al 25% inferiore dei pagatori di dividendi nel mercato Spanish ( 2.36% ).

Dividendo elevato: Il dividendo di ALM ( 2.16% ) è basso rispetto al 25% dei maggiori pagatori di dividendi nel mercato Spanish ( 5.55%.

Distribuzione degli utili agli azionisti

Copertura degli utili: ALM sta pagando un dividendo ma la società non è redditizia.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: ALM sta pagando un dividendo ma la società non ha flussi di cassa liberi.

Almirall Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Third quarter 2024 earnings released

Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024

Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Second quarter 2024 earnings released

Almirall, S.A. Reiterates Financial Guidance for Full Year 2024

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Insufficient new directors

Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year

Dividend of €0.15 announced

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Almirall, S.A., Annual General Meeting, May 10, 2024

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 29%

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Now 21% undervalued

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

New minor risk - Shareholder dilution

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

New minor risk - Dividend sustainability

Is Almirall (BME:ALM) A Risky Investment?

First quarter 2023 earnings released

Consensus EPS estimates fall by 26%

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued after recent price drop

Price target decreased by 7.2% to €11.93

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Now 20% undervalued

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings: EPS misses analyst expectations

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Now 21% undervalued

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Now 22% undervalued

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Price target decreased to €14.66

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020)

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis